Asston Pharmaceuticals Board of Directors
Get the latest insights into the leadership at Asston Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Dr. Ashish Narayan Sakalkar | Managing Director |
| Ms. Saili Jayaram More | WholeTime Director & CEO |
| Mr. Sachin Chandrakant Badakh | Non Executive Director |
| Mr. Rishabh Kumar Jain | Ind. Non-Executive Director |
| Ms. Vijaya Shahpurkar | Ind. Non-Executive Director |
Asston Pharmaceuticals Share price
APL
102.49
1.62 (1.61%)Last updated on 4 Sep, 2025 | 13:52 IST
BUYSELL
Today's High
102.49
Today's Low
100.87
52 Week Low
96.00
52 Week High
126.00
The current prices are delayed, login to your account for live prices
LoginAsston Pharmaceuticals FAQs
The board at Asston Pharmaceuticals consists of experienced professionals, including Dr. Ashish Narayan Sakalkar , Ms. Saili Jayaram More , and others, overseeing the company’s strategic and corporate governance.
Directors at Asston Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Dr. Ashish Narayan Sakalkar is the current chairman at Asston Pharmaceuticals.
Executive directors at Asston Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Asston Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Asston Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.